Multiple keratoacanthomas

Kopf, A. W.

doi:10.1001/archderm.103.5.543

Cited by 13 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But whether trauma plays a part in DKA has not been shown conclusively. Kopf 8 reported a patient who had had numerous KAs since the age of 12 years. They appeared on his fingertips at the site of punctures made to obtain blood.…”

Section: Discussionmentioning

confidence: 99%

Distal digital keratoacanthoma: a report of 12 cases and a review of the literature

Baran

Goettmann

1998

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Distal digital keratoacanthoma: a report of 12 cases and a review of the literature

Baran

Goettmann

1998

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…A potential mechanism for the involution of the KA after MTX treatment is the decrease in DNA synthesis in the rapidly dividing tumour (10). Certain patients, however, are unable to tolerate systemic MTX due to the adverse effects while, in others, the KAs do not respond to systemic MTX (11).…”

mentioning

confidence: 99%

Treatment of keratoacanthoma: Is intralesional methotrexate an option?

Patel¹,

Cervino²

2011

J Plastic Surgery

View full text Add to dashboard Cite

“…Other modalities have been used to treat keratoacanthomas in some patients—particularly those individuals who were not surgical candidates. In addition to routine and Mohs microscopically controlled surgical excision, 12 alternative successful therapies for treating keratoacanthomas include corticosteroids, 13,14 cryotherapy, 9 curettage and electrodesiccation, 7,15 cytotoxic agents, 2–6,8–11,13,14,16–21 immune modulators, 2,22,23 radiotherapy, 24,25 and retinoids 2,16,26 . The therapeutic agents have been administered either intralesionally, 8–14,16,19–21 IM, 13,18 IV, 4,6 orally, 2–7,17,26 subcutaneously, 2 or topically 13,17 …”

mentioning

confidence: 99%

“…Certain patients are unable to tolerate systemic methotrexate therapy; they develop medication‐associated adverse reactions requiring discontinuation of the drug 6 . In addition, other patients have had keratoacanthomas that did not respond to treatment with systemic methotrexate 2–4,17 …”

mentioning

confidence: 99%

Intralesional Methotrexate for Keratoacanthoma of the Nose

R.¹,

E.²,

F.³

et al. 2005

Skinmed

View full text Add to dashboard Cite

A 56-year-old woman developed a nodule on her nose. A shave biopsy of the enlarging lesion was performed after 2 weeks and showed a keratoacanthoma. During the subsequent 4 weeks, the lesion continued to grow rapidly, and she was referred for excision of the lesion using the Mohs microscopically controlled technique. A tender 10x12 mm (120 mm2) erythematous nodule with a keratin-filled central umbilication was present on her left nasal ala (Figure 1). Treatment options were discussed. The left nasal ala was locally anesthetized with 1% lidocaine with 1:100,000 epinephrine and the keratoacanthoma was circumferentially infiltrated with 10 mg of methotrexate (0.8 mL of 12.5 mg/mL methotrexate) using a 30-gauge needle. The total amount of methotrexate injected was divided among several injection sites: the peripheral shoulder of the lesion (such that there was blanching of the entire rim) and under the center of the lesion at a depth clinically judged to be the deepest area of involvement. Within the next 7 days, the tumor began to decrease in size and ulcerate centrally. Examination 2 weeks after the initial injection showed a 71% reduction in the area of the tumor, which now measured 35 mm2 (7.0x5.0 mm). The tumor was injected in a similar manner as before with 5 mg of methotrexate. After another 2 weeks, the tumor had continued to shrink. It was flat without nodularity and measured 12 mm2 (4.0x3.0 mm); the tumor area was 66% less than 2 weeks earlier and 90% less than its original size. The residual tumor was again injected with 4.5 mg of methotrexate. There was complete clinical involution of the tumor when the patient returned for evaluation 6 weeks after her initial injection of methotrexate (Figure 2). A biopsy of the lesional area to confirm histologic resolution of the keratoacanthoma was not performed since there was no visible residual tumor. Periodic follow-up examination has been performed and there has been no subsequent recurrence of the keratoacanthoma.

show abstract

Multiple keratoacanthomas

Cited by 13 publications

References 0 publications

Distal digital keratoacanthoma: a report of 12 cases and a review of the literature

Distal digital keratoacanthoma: a report of 12 cases and a review of the literature

Treatment of keratoacanthoma: Is intralesional methotrexate an option?

Intralesional Methotrexate for Keratoacanthoma of the Nose

Contact Info

Product

Resources

About